Myelodysplastic syndromes are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, peripheral cytopenias, and a variable propensity for leukemic transformation. In recent years there has been an explosion of information on the molecular genetic changes underlying these disorders. This information has substantial prognostic implications, and the influence on therapeutic approaches and the treatment of patients is evolving. Allogeneic hematopoietic stem cell transplantation (alloSCT) is the only known cure for these diseases, but appropriate patient selection is of utmost importance from a risk-benefit perspective. This review focuses on the factors influencing risk stratification in MDS and optimal choice of front-line therapy in the current era, including the interplay of clinical factors and molecular genetic factors, and factors that determine eligibility for alloSCT. The myelodysplastic/myeloproliferative diseases also will be discussed, including the increasing effort to understand the molecular genetics and natural history of these disorders and treatment approaches.
T he myelodysplastic syndromes are a clinically and molecularly heterogeneous group of clonal stem cell disorders with management options ranging from observation and growth-factor therapy to more intensive approaches, such as hypomethylating agent (HMA)-based therapies, intensive induction chemotherapy, and alloSCT. 1 During the last decade, rapid developments centered around highthroughput molecular technologies have resulted in remarkable advancement toward the understanding of MDS pathogenesis. [2] [3] [4] [5] [6] These technologies are anticipated to translate to innovative targeted agents that will radically affect the natural history of this disease. Presently, however, alloSCT remains the only curative treatment option in patients with MDS. 2, [7] [8] [9] Even if substantially reduced during the last 20 years, mortality and morbidity risks associated with alloSCT continue to represent a major limit to the feasibility of such a therapeutic strategy in the large number of patients. 8, 10, 11 Therefore, the accurate selection of patients-together with optimal timing of transplantation-represent critical issues for maximum improvement of the alloSCT risk-benefıt ratio in MDS.
As such, important advancements have been made toward the dissection of MDS clinical heterogeneity that have incorporated both clinical and molecular characteristics. In this review, we will discuss recent refınements to prognosis for patients with MDS based on clinical, cytogenetic, and molecular risk factors. We also will discuss the approach to the selection of front-line therapy in MDS, including a particular focus on alloSCT. Lastly, we will highlight myelodysplastic/ myeloproliferative neoplasms (MDS/MPNs), including recent insights into the molecular genetics and emerging therapeutic approaches in patients with these diseases.
PROGNOSTIC STRATIFICATION IN MYELODYSPLASTIC SYNDROMES
MDS is a disease found in older adults, with a median age at diagnosis of age 71. The estimated 3-year survival rate of patients with MDS is 45%, 12 although there is substantial variability in outcomes even within the same French-AmericanBritish (FAB) 13 classifıcation system and the more recent World Health Organization (WHO) morphologic subtypes. 14 This heterogeneity in outcomes underscores the need for accurate prognostication and has fuelled the evolution of various prognostic scoring models.
Prognostic Classification Models
The international prognostic scoring system (IPSS), a widely validated system currently in use, originally was created from data from 816 patients. The IPSS encompasses karyotype, blast percentage, and the number of cytopenias, thus stratifying patients with de novo MDS into four risk categories. These include lower risk MDS comprising low and intermediate-1 risk categories, and higher risk MDS comprising intermediate-2 and high-risk categories; with median survivals ranging from 5.7 to 0.4 years. 15 Limitations associated with the IPSS include the lack of consideration of the severity of cytopenias, and transfusion dependency; underweighting of the prognostic import of karyotype relative to marrow blast-percent; and the fact that this model is applicable only at diagnosis. Several of these limitations were addressed by the development of other models, including the WPSS, 16 which incorporates transfusion dependency and WHO subtype, among other factors. It is a dynamic model that can be applied at diagnosis and follow-up. The University of Texas MD Anderson Cancer Center (MDACC) prognostic model includes a broader population of patients, such as patients with therapy-related MDS and patients with chronic myelomonocytic leukemia (CMML). 17 An additional prognostic model focused on lower-risk disease (LR-PSS) has been developed at MDACC. 18 The revised IPSS (IPSS-R), 19 which was created from an evaluation of more than 7,000 patients, incorporates a comprehensive 5-tiered cytogenetic risk stratifıcation system that comprises 15 cytogenetic subtypes (Table 1) . 20 It also accounts for the degree of cytopenias and provides a more discriminant assessment of bone marrow-blast percentage. The predictive value of cytogenetics in MDS has long been recognized, and the comprehensive cytogenetic strata included in the IPSS-R assure that chromosomal aberrations of prognostic importance are accorded appropriate weight in the model relative to bone marrow blast-percent. Five risk groups are identifıed-very low, low, intermediate, high, and very-high with median survival ranging from 8.8 to 0.8 years.
Similar to the IPSS, the IPSS-R was generated on data from patients evaluated at diagnosis and censored at the time of receipt of disease-modifying therapy. Despite these issues, the IPSS-R has been rapidly validated by several groups to be more discriminant than the IPSS and the WPSS, 21 and to retain its predictive value even in patients treated with diseasemodifying agents. 22, 23 Therefore, in just a few short years since its introduction, IPSS-R is rapidly being adopted as the preferred clinical prognostic tool for risk stratifıcation in MDS.
The Evolving Role of Molecular Genetics on Risk Prediction
A comprehensive evaluation of the prognostic relevance of point mutations in refıning risk stratifıcation in MDS was fırst established in a study of 439 patients with MDS. 24 Using next-generation DNA sequencing and mass spectrometry genotyping to evaluate 111 genes, mutations in fıve genes (TP53, EZH2, ETV6, RUNX1, and ASXL1), which collectively occurred in approximately one-third of patients, were found to confer poor risk prognosis, independent of established clinical risk factors such as IPSS. Within each IPSS subgroup, the presence of one or more of these mutations was demonstrated to result in a decline in overall survival, which approximated that of the next-highest IPSS risk group. 24 The same group has since validated the prognostic effect of these mutations (EZH2, RUNX1, TP53, and ASXL1) in patients with lower-risk MDS. The presence of these mutations was found to be associated with a shorter overall survival independent of the LR-PSS. 25 In a multivariate analysis that included LR-PSS and other mutations, only EZH2 mutations retained independent prognostic signifıcance. The clinical implication of upstaging for the risk group is recognition that patients in lower-risk IPSS categories have a worse prognosis, which may result in consideration of more intensive treatment approaches for such patients. 24, 26 It is now evident that more than 40 genes are mutated in MDS. 4, [27] [28] [29] Approximately 90% of patients with MDS harbor at least one mutation, with a median of two or three mutations detected per patient (range, 1 to 12). Mutations could be categorized into subgroups that affect specifıc functional pathways ( Fig. 1) , including the spliceosome machinery (SF3B1, SRSF2, U2AF1, U2AF2, ZRSR2); DNA methylation (TET2, DNMT3A, IDH1, IDH2); chromatin modifıcation (ASXL1, EZH2); RAS and other kinase signaling pathways (NRAS, KRAS, CBL, JAK2); transcription factor (TP53, RUNX1, EV1, GATA2); cohesin; and DNA repair pathways. Of these, mutations affecting RNA splicing and epigenetic dysregulation (DNA methylation and chromatin modifıca-tion) were commonly observed, underscoring the critical importance of these pathways in MDS pathogenesis. In particular, more than 50% of patients had a mutation in a component of the spliceosome machinery, identifying prem-RNA splicing as the most frequently altered biologic pathway in these diseases.
These studies also provided several additional insights into the role of the molecular genetic profıle in determining clinical and phenotypic heterogeneity associated with the disease. For example, the high frequency (75%) of SF3B1 mutations in MDS subtypes associated with ring sideroblasts was confırmed, implying that this mutation is a signifıcant predictor for the presence of ringed sideroblasts in the marrow. Only mutations in SF3B1 were associated with a better clinical outcome. In contrast, the average number of mutations was higher per patient in the higher-risk WHO morphologic categories (i.e., refractory anemia with excess blasts (RAEB1 and RAEB-2), which is consistent with a higher degree of clonal evolution in these subtypes). Leukemia-free survival in patients with MDS was found to negatively correlate with the combined number of oncogenic and cytogenetic lesions. The number ranged from 49 months in patients with one lesion to 4 months in patients with six or more mutations. Furthermore, the number of oncogenic mutations provided independent prognostic information after stratifı-cation by the IPSS. 4 Insights into clonal evolution and clonal architecture of MDS also have been obtained from studies 4, 30 with mutations in genes involved in RNA splicing or epigenetic regulation with a higher variant allele fraction, which suggests that these mutations occurred earlier during clonal evolution. Both clonal and subclonal events within the same genes, however, retained similar prognostic signifıcance. This suggests that the fınding of a mutation in a minor subclone is clinically relevant, thus emphasizing the potential utility of a targeted deep-sequencing approach that is sensitive enough to detect minor subclonal events.
Mutations within the same functional pathways often were mutually exclusive (e.g., TET2 and IDH1/2 mutations, which both affect DNA hydroxymethylation). Similarly, mutations involving the spliceosome machinery rarely co-occur. Biologically relevant interactions also were found in patterns of co-occurrence. For example, SF3B1, which is associated with good prognosis, was mutually exclusive with ASXL1 and IDH2, which both confer a poor prognosis. However, SRSF2 showed a clear propensity to associate with TET2 and its comutation is highly associated with monocytosis. 4, 27, 31 It is plausible that such biologic insights also will be of clinical value in the design and use of targeted therapies.
These molecular profıling efforts successfully demonstrate that the integration of clinical, morphologic, and cytogenetic information already encompassed by the IPSS and IPSS-R, along with the comprehensive molecular genetic profıle now available via targeted deep sequencing techniques, has the potential to substantially refıne risk stratifıcation in MDS. 27 In the 21st century, it is highly anticipated that such combined risk models-once validated prospectively-will enter into common clinical use to refıne prognosis and potentially determine treatment approaches for patients with MDS.
FRONT-LINE THERAPY IN MYELODYSPLASTIC SYNDROMES
The concept of individualized therapy is particularly relevant in the selection of optimal therapeutic strategies in this disease, and it should incorporate a consideration of both patient-and disease-specifıc elements. Higher-risk patients generally are offered more intensive therapeutic options, including HMA therapy and an early consideration of stem cell transplantation, which is discussed in substantial detail below. Lower-risk patients are offered therapies that range from observation (in patients who are asymptomatic with relatively well-preserved blood counts), to growth factors 27 ODENIKE, ONIDA, AND PADRON e400such as erythropoietin (in patients with anemia), to immunosuppressive therapy (in patients with multiple cytopenias). Therefore, elements that factor into risk stratifıcation are of critical therapeutic importance. Contemporary approaches to risk refınement, including the use of more discriminant prognostic models, such as the IPSS-R, are highly encouraged. Data are evolving to support the potential utility and applicability of models that combine comprehensive targeted molecular profıling with clinical models, such as the IPSS-R, in making treatment decisions, and they deserve prospective validation.
Supportive Care/Growth Factor Therapy
Lower-risk patients with anemia may benefıt from erythropoietin (EPO) therapy. Predictors of response include lower serum EPO level (Ͻ 500 U/L) and a lower transfusion requirement (Ͻ 2 units of red cells per month). Response rates in such patients may be as high as 60%; however, it is substantially lower (less than 10%), in the absence of the above criteria. 32 Since most responses to EPO will occur within 8 weeks, a time limited trial of 8 weeks is reasonable when EPO is being used for treatment of MDS.
Immunosuppressive Therapy
Immunosuppressive therapy (IST) with antithymocyte globulin (ATG)-based therapies 33 are reasonable to consider in lower-risk patients with MDS who have multiple cytopenias, who are younger (Ͻ age 55), and who are positive for the HLA DR15 allele. These latter factors were positive predictors of response to IST. 34 A hypocellular marrow, which suggests a disease more closely aligned with aplastic anemia, also has been found in some studies to be predictive of response, but it has not been confırmed in others. 35, 36 Since activated T cells are the target of IST, a predictive model that consists of a T-cell activating signature and duration of disease also has been proposed. 37
Lenalidomide
In patients with deletion 5q (del[5q]) and lower-risk disease who require red cell transfusions, the use of lenalidomide is associated with a transfusion independence rate in the 70% range, with a median duration of response of 2.2 years. 38 In lower-risk patients with MDS without the del(5q), the response rate is in the 25% range and response duration is substantially shorter. 39 High karyotypic complexity, lower platelet count, and TP53 mutations tend to be associated with lenalidomide resistance, even in the presence of del(5q). 40 Lenalidomide currently is being investigated in combination with erythropoietin in a phase III trial in lower-risk patients with MDS. In this trial, it is hypothesized that the combination of lenalidomide and EPO will potentiate erythroid response in patients who have failed to respond to EPO or in whom EPO is predicted to have a low probability of being effective. The trial is based at least in part on promising results from an early phase trial that investigated the combination. 41 Recently, a novel mechanism of action involving lenalidomide-induced degradation via cereblon-of casein kinase 1, alpha-1 (CSNK1A1), located on 5q32, and which results in further reduction of haploinsuffıcient expression of CSNK1A1-has been implicated in the sensitivity of del(5q) MDS to lenalidomide. 42
Hypomethylating Agents
The U.S. Food and Drug Administration (FDA) has approved hypomethylating agents (HMAs) 5-azacytidine (azacitidine) and 5-aza-2Јdeoxycitidine (decitabine) for treatment of patients with MDS. These compounds become incorporated into DNA-although azacitidine also gets incorporated into RNA-and form a covalent complex with the DNA methyltransferase (DNMT) enzyme, which results in trapping and degradation of the enzyme and progressive loss of DNMT activity within the cells and subsequent DNA hypomethylation. When administered at very high doses, the cytotoxic effects of the agents predominate. However, lower doses in the range used for treating patients with MDS are postulated to allow the hypomethylating effect and, thus, epigenetic modulation to occur. 43 Both agents have been investigated in randomized trials of patients with MDS. They are associated with similar objective response rates of complete response and partial response in the 15% range, although an additional 15% to 30% of patients will experience hematologic improvement, manifested primarily as an improvement in cytopenias and transfusion requirements. [44] [45] [46] Improvements in quality of life also have been demonstrated.
In addition, azacitidine has been associated with an overall survival advantage in patients with higher-risk MDS, when compared to prespecifıed conventional care regimens (including supportive care, low-dose cytarabine, and acute myeloid leukemia (AML) type-induction therapy), with median survival of 24.5 months in the azacitidine arm compared with 15 months in the control arm. 44 A population-based study also confırmed this 24-month survival benefıt with azacitidine use outside of a clinical trial setting. 47 Although the benefıt associated with the use of HMAs in patients with MDS is indisputable, many patients will not benefıt from them. Furthermore, for those who respond, the response is not immediate. The median time to best response is in the range of 3 to 4 months. Therefore, biomarkers that predict response to therapy would be of substantial value. Our increasing knowledge of the molecular genetic landscape of MDS-including the fact that mutations affecting enzymes that are involved in DNA methylation are involved in MDS pathogenesis-has spurred additional efforts in recent years to fınd predictive biomarkers to HMA therapy. As such, TET2 mutations or DNMT3A mutations were associated with a modest increase in response rates to HMA therapy in earlier reports with conventional Sanger sequencing. 48, 49 A more recent report used a more comprehensive molecular profıling approach. It evaluated 40 recurrently mutated genes in 213 patients with MDS treated with HMAs and confırmed clonal TET2 mutations as predictive of response (odds ratio, 1.99). 50 In contrast, TP53 and PTPN11 mutations were associated with shorter overall survival after HMA treatment, but they did not predict response. These fındings require validation in prospective clinical trials. Presently, insuffıcient evidence exists to suggest that the decision to treat patients with HMAs can be made on the basis of mutational profıling alone, especially since responses to HMAs were observed even in patients with mutations that confer a very poor prognosis. 50 
Combination Therapies
There remains an urgent need for the development of new drug therapies and combinations to treat patients with MDS. An early focus was the combination of HMAs with histone deacetylase inhibitors (HDACi). [51] [52] [53] [54] [55] This was based on the hypothesis that inhibiting two pathways of epigenetic deregulation would be potentially synergistic, and abundant preclinical evidence of synergy. Early phase trials investigating the combination of azacitidine with the HDACi entinostat or vorinostat, 52, 56 or the immunomodulatory agent lenalidomide, 57 yielded promising results, which has led to randomized trials conducted in the intergroup setting.
The results of randomized trials conducted in the U.S. intergroup setting (E1905) comparing azacitidine versus azacitidine plus entinostat, 58 and preliminary results of the recently concluded three-arm randomized phase II North American intergroup trial (S1117) comparing single-agent azacitidine to azacitidine plus vorinostat and azacitidine plus lenalidomide combinations, 59 respectively, however, have shown no signifı-cant advantage to the combination arms as to improvement in response rates. Therefore, azacitidine remains the standard of care. Survival endpoints, either progression-free or overall survival, may be more relevant primary endpoints of future large randomized efforts that compare single-agent HMA therapy to novel combinations and approaches.
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Individual decision making on whether to consider alloSCT as a possible treatment option in treating patients with MDS requires the accurate assembling of several disease-and patient-characteristics.
Disease Characteristics
In general, MDS includes an extremely heterogeneous group of myeloid malignancies with different natural courses and life expectations. Therefore, a risk-based approach for individual decision making on treatment strategy is highly suggested, and it is mandatory when referring patients for alloSCT. 8, 10, 60 Together with the nosological classifıcation methods (such as the FAB and, more recently, the WHO classifıcation schemes), prognostic scoring systems in MDS have been considered the most appropriate tools for treatment stratifıcation. For almost 15 years, the IPSS 15 has been universally recognized as the landmark reference method for risk-stratifıcation with patients classifıed in high-risk categories (including intermediate-2 and high-risk groups) as generally being considered for early alloSCT. However, a different treatment plan usually is recommended for patients in the lower IPSS risk categories (i.e., low and intermediate-1). In a foremost decision-analysis study that included patients younger than age 60, delayed transplantation was shown to associate with maximal life expectancy, with an even more marked survival advantage for patients under age 40. 61 In 2007, a time-dependent WHO classifıcation-based prognostic scoring (WPSS) incorporating transfusion dependence was proposed for untreated patients. 16 Different from IPSS, the WPSS identifıes fıve risk groups of patients with different survival, and it allows for real-time assessment of prognosis in MDS. Its relevance after alloSCT was validated in a subsequent study from the GITMO group that included 406 patients, 62 in which a multivariate Cox survival analysis also included age and sex of patient, time between diagnosis and alloSCT, year of transplantation, disease stage at transplantation, source of stem cells, type of donor, and type of conditioning, WPSS showed a prognostic signifıcance on both overall survival and probability of relapse. The validity of WPSS in predicting outcomes after alloSCT in patients with MDS recently was confırmed in a population of 60 Southeast Asian patients. 63 Cytogenetics appears to be the most critical factor in determining survival in patients with MDS. However, the cytogenetic categories included in all of the proposed prognostic scoring systems were derived from large series of patients who were only treated with supportive care. Because alloSCT represents a treatment strategy that is potentially capable of eradicating the hematopoietic malignant cell clone, it could be postulated that the prognostic signifıcance of cytogenetics would persist using this treatment approach. However, the negative effect of poor-risk cytogenetics on the outcomes of patients with MDS undergoing alloSCT has been confırmed. [64] [65] [66] [67] [68] [69] For example, a recent retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT) demonstrated that poor-risk cytogenetics, as defıned by standard IPSS scores, were associated with a relatively poor survival after alloSCT from HLA-identical siblings, except in patients with low marrow blast count (i.e., RA/RARS) who were transplanted up front. 69 In 2012, the revised IPSS (IPSS-R) for MDS was generated by analyzing 7,012 patients in a new international collaborative effort. Based on a new comprehensive cytogenetic score, 20 and considering severity of cytopenias by incorporating different cutoff points, the IPSS-R stratifıes fıve risk groups with different clinical outcomes. 19 The ability of the new cytogenetic risk classifıcation to predict post-transplant outcome was promptly confırmed in a series of 1,007 patients who underwent alloSCT at the Fred Hutchinson Cancer Research Center in Seattle. A substantially higher rate of relapse and mortality rate was found in patients with very poor cytogenetics compared to patients with good-risk cytogenetics. 70 An additional disease characteristic recently has been shown to negatively affect the prognosis of patients with MDS. Not included in any of the previously described scoring systems is the presence of a monosomal karyotype (MK) (i.e., the presence of two or more distinct autosomal monosomies or a single monosomy associated with a structural abnormality). [71] [72] [73] [74] However, an association of MK with lower survival, higher relapse incidence, and overall mortality after alloSCT-even among patients with a complex karyotypehas been reported consistently. 70, [75] [76] [77] The effect of the IPSS-R on alloSCT outcomes recently was demonstrated in an analysis from the Italian GITMO cooperative group that included 374 patients with primary MDS. Both IPSS-R and monosomal karyotypes were independently associated to a lower overall survival and a higher relapse probability by multivariate analysis. 78 In this study, a predictive model of post-transplant outcome in patients with MDS (Transplantation Risk Index) was originated based on the age of the patient, IPSS-R category, monosomal karyotype, hematopoietic cell transplantation (HCT)-specifıc comorbidity index, and refractoriness to induction chemotherapy.
In addition to cytogenetics, other disease characteristics have been associated with a poor prognosis in patients with MDS. These include severe bone marrow fıbrosis, 79,80 refractory lifethreatening cytopenias, [81] [82] [83] and gene mutations. 2, 18, 24, 25, 28, 29, [84] [85] [86] [87] [88] [89] As to the effect on alloSCT outcome, bone marrow fıbrosis, a recent EBMT retrospective analysis of 721 patients with MDS demonstrated that only severe fıbrosis was shown to affect survival, whereas patients with mild or moderate fıbro-sis had an alloSCT outcome comparable to patients without bone marrow fıbrosis. 79 For gene mutations, an independent association with a shorter post-transplant overall survival, after adjusting for clinical variables and complex karyotype status, recently has been reported for mutations in TP53 and TET2. 90 
Patient Characteristics
Apart from disease characteristics, host-specifıc risk assessment in determining indications for alloSCT always should be grounded on essential patient-related factors, including age, comorbidities, and donor availability.
Although usually considered as a treatment option for patients younger than age 60, over the last 2 decades the development of reduced-intensity conditioning (RIC) regimens, together with substantial progress in supportive care measures, have resulted in an increase in the upper age limit to age 70 (occasionally even older) in carefully selected very-fıt patients. Because MDS are much more common in older people (median age at diagnosis, over age 70), with only 10% of patients younger than age 50, this age-limit extension translates to a considerable expansion in the proportion of patients for whom an alloSCT treatment strategy might be presently contemplated. 91, 92 Indeed, an international collaborative retrospective comparison of two well-balanced cohorts of medically fıt patients with high-risk MDS defıned by age 60 to 70 and ECOG PS of 2 or less, treated with alloSCT (103 patients) in case of donor availability, or 5-azacytidine (75 patients) in case of no donor availability, suggested a survival advantage in favor of allogeneic transplantation. 93 Additionally, recently reported results of an international collaborative decision analysis (evaluating both life expectancy and quality-adjusted life expectancy) indicated a signifıcant benefıt (p Ͻ 0.001) of RIC alloSCT versus nontransplantation therapies in patients' age 60 to 70 with intermediate-2/high-risk IPSS de novo MDS. 94 However, a sophisticated statistical analysis of a large population of older patients with advanced MDS compared alloSCT (247 patients, reported to the EBMT) with nontransplant approaches (137 patients, reported to the Düsseldorf registry). The analysis indicated a possible nonsignifıcant survival disadvantage for the transplant cohort because of the higher nonrelapse mortality. 95 These results suggest that a prospective controlled randomized study that addresses the "intention to go for transplant" question is absolutely necessary. 95 Comorbidities have been shown to crucially affect alloSCT clinical outcomes in several hematological malignancies. These data led to the development of a hematopoietic cell transplantation-specifıc comorbidity index (HCT-CI) as a useful tool for risk assessment before transplantation. 96 The risk-stratifıcation ability of the HCT-CI in patients transplanted for AML and MDS subsequently was confırmed both in the reduced-intensity and myeloablative conditioning strategies. [97] [98] [99] [100] The HCT-CI also was prospectively validated by the GITMO group in a consecutive cohort of 1,937 patients receiving alloSCT in Italy over 2 years, including 199 patients with MDS. In 2011, a time-dependent MDS-specifıc Comorbidity Index (MDS-CI) was developed on a learning cohort that included 840 patients diagnosed in Pavia, Italy. It was subsequently validated in an independent cohort of 504 patients diagnosed in Düsseldorf, Germany. 101 Since it has been shown to provide additional prognostic information on patients stratifıed according to the IPSS-R, the MDS-CI may represent a valuable tool in support of the HCT-CI when evaluating patients for possible transplant indication.
High-serum ferritin and iron overload secondary to pretransplantation transfusion also is associated with a substantial negative effect on nonrelapse mortality after alloSCT. 102-110 Thus, transfusion history in patients with MDS should be considered for transplantation decision-making as well as for initiation of a timely iron chelation therapy to prevent iron accumulation before transplant.
When to Transplant
Although very heterogeneous, the natural course of MDS typically is characterized by a disease progression with patients exhibiting gradual worsening of peripheral blood cytopenias, which eventually lead to transfusion dependency. Sequential marrow examination, especially in the presence of myeloblast excess (i.e., Ն 5%), often can demonstrate an increase in marrow blast-count culminating in AML evolution. Cytogenetics tend to remain stable, even though the occurrence of chromosome aberrancies (or additional ones, when already present at diagnosis) occasionally may be observed. Time-dependent disease modifıcations are outlined as phase progression by the WPSS and the IPSS/IPSS-R classifıcation system, IPSS-R. 15, 16, 19 The Markov retrospective analyses cited above have shown a substantial survival advantage for patients who are in highrisk categories of MDS (intermediate-2 and high-risk, according to IPSS) undergoing early alloSCT from HLAmatched donor, whereas a transplant deferment until disease progression seems to confer longer life expectancies in patients with lower-risk MDS (low-and intermediate-1 risk, according to IPSS). 61, 94 In general, because the status of the disease at transplant has a major effect on all outcomes, better long-term results seem to be achieved when transplantation is performed earlier during the course of the disease. 62, 111, 112 In addition to disease progression, risk associated with transplant delay may include occurrence of infectious complications, acquisition of transfusion refractoriness, iron overload secondary to transfusion history, performance status decline, and acquisition of additional comorbidities, which lead to a substantially higher risk of nonrelapse mortality following transplantation. Nonetheless, the question of the optimal time for alloSCT in individual patients may be diffıcult, because of the unavoidable morbidity and nonrelapse mortality risks associated with the transplantation procedure and to the current availability of alternative treatment options, such as HMAs. In a recent GITMO decision study that included 660 patients with MDS who received best supportive care and 449 who underwent transplantation, a continuous-time multistate Markov model was applied to describe the natural history of the disease and to evaluate the effect of alloSCT on survival. 113 Results of this study indicate that a delayed transplantation is advisable only for patients with early disease (low-risk by IPSS, very low-and low-risk by WPSS), with the best survival benefıt deriving from alloSCT for patients classifıed in the intermediate-1, according to IPSS (in the presence of multilineage dysplasia and/or transfusion dependency) or the intermediate WPSS risk category.
Furthermore, new and interesting information that could be combined for clinical decision making in patients with MDS may originate from a further retrospective GITMO study. This study was recently performed in a large population of 529 patients with MDS without a compatible family donor but with plain indication for alloSCT. A competing risk analysis unveiled high pretransplant risk of disease evolution and mortality resulting from the time spent waiting for the identifıcation of a suitable unrelated donor, both on the entire population of patients with MDS and on specifıc subgroups stratifıed by disease risk and age (GITMO Registry, M. Della Porta, personal communication, 2015) . If confırmed in other series, these fındings would support selection of haploidentical donors to perform immediate alloSCT in patients with high-risk MDS without a promptly available HLA-matched donor. 114, 115 Apart from obviously depending on donor availability, the decision on when to transplant in MDS often has to consider potential treatment to be administered before transplantation, especially in patients with a higher percentage of marrow to possibly downstage the disease to a lower-risk category. [116] [117] [118] Because AML-like induction chemotherapy, besides being rather toxic in older patients, is frequently leading to disappointing results in MDS, especially in the presence of high-risk cytogenetics, HMAs frequently are preferred in the interim period before transplantation. Life expectancy has been shown to be very dismal for patients with loss of response to azacitidine. 119, 120 In patients whose disease responds, alloSCT possibly should be offered before disease progression, if a donor is available. Presently, because of the absence of randomized studies, optimal pretransplantation therapy is unknown, 121 although trials with HMAs employed as a bridge to transplant are currently ongoing.
In conclusion, individual decision making on the best treatment strategy pertaining to allogeneic transplantation is usually the consequence of a diffıcult composite judgment that includes disease-, patient-, and transplant-characteristics together with the patient's expectations and opinions.
GENETICS IN MYELODYSPLASTIC SYNDROMES/MYELOPROLIFERATIVE NEOPLASMS
MDS/MPNs represent an optimal disease model for the clinical implementation of broad spectrum mutational profıling. First, the clinical and pathologic characteristics of MDS/ MPNs are challenging to recognize, and they often can change within the context of cytoreductive agents or other therapies. Second, the spectrum of mutations in MDS/MPNs is relatively well-characterized and allow for the sensitive annotation of clonality in most patients. Lastly, although substantial overlap occurs among recurrent mutations in MDS/MPNs, it could be argued that each disease entity is characterized by a unique genetic fıngerprint that may aid in diagnosis. Emerging evidence suggests that these genetic lesions are independently prognostic and may aid in therapeutic decisions. Below is a disease-specifıc summary of recurrent mutations and their clinical relevance (Table 2) .
Chronic Myelomonocytic Leukemia
The hematologic phenotype of chronic myelomonocytic leukemia (CMML) is defıned by a peripheral monocytosis and dysplasia. 122 The recurrent genetic mutations associated with this CMML phenotype converge on diverse pathways that include mutations of signal transduction (NRAS, KRAS, CBL, JAK2); DNA methylation (DNMT3A, TET2, IDH 1/2); transcriptional regulation (ETV6, RUNX1) ; chromatin modifıca-tion (EZH2, ASXL1); and the RNA splicing machinery (SF3B1, SRSF2, ZRSR2, U2AF1) . [123] [124] [125] Although the pathways affected are heterogeneous, a genetic clonal event can be identifıed in greater than 90% of CMML cases by sequencing only nine genes. In fact, mutations in TET2, ASXL1, and SRSF2 are highly recurrent with each identifıed in up to 45% of patients. [125] [126] [127] This allows for the CMML clinician to obtain evidence of clonality in almost all cases of suspected CMML, making it straightforward to parse malignant from reactive monocytosis. Additionally, co-mutation of SRSF2 and TET2 is highly specifıc for patients with CMML, which aids in the diagnosis of the treated CMML patient when historic monocytosis may be unclear and current monocytosis may be suppressed by HMAs or cytoreductive agents. 31 The prognostic signifıcance of recurrent mutations in CMML also has been tested. Interrogation of the most common mutations in CMML has identifıed ASXL1 to be independently prognostic. 48, 73 This has led to its incorporation into two independent prognostic scoring systems. However, larger data sets will be required to fully annotate the prognostic signifıcance of single and combination mutations in CMML.
Juvenile Myelomonocytic Leukemia
Although the monocytic phenotype of juvenile myelomonocytic leukemia (JMML) is similar to that of CMML, the genetic fıngerprint of JMML is distinct. 128 Greater than 90% of recurrently mutated genes in JMML cluster on RAS pathway activation. 129 These gene mutations include NF1, N-RAS, K-RAS, PTPN-11, and CBL. 130, 131 Both somatic and germline mutations of these genes have been identifıed, with the latter most associated with congenital genetic syndromes such as Noonan syndrome (PTPN11) and Neurofıbromato-sis type 1 (NF1). [132] [133] [134] Secondary events in JAK3 and SETBP1 also have been described and suggest a poor prognosis. 135, 136 This genetic landscape, along with its characteristic GM-CSF hypersensitivity, has resulted in major advances in the molecular understanding of JMML. 128 Further, the presence of these mutations can alter treatment decisions and management. Patients with CBL mutations and its associated congenital syndrome can manifest a JMML phenotype that is self-limited. 131 Therefore, a watchful waiting strategy is often employed in these children, as opposed to allogeneic transplant in other RAS-mutated JMML cases. 137 
Atypical Chronic Myeloid Leukemia
Atypical chronic myeloid leukemia (aCML)Atypi is a disease characterized by severe neutrophil dysplasia and cytopenias in the absence of the BCR:ABL fusion protein. This disease has historically been diffıcult to diagnose given the pathologic overlap between it and other MDS/MPNs, particularly MDS/MPN-Unclassifıable. Further, the diagnostic diffıculty present in discerning aCML from chronic neutrophil leukemia (CNL) has made the annotation of aCML-specifıc mutations challenging. 138 Gene mutations identifıed in aCML/ CNL include JAK2, SETBP1, NRAS, and CSF3R. Analysis of these genes can identify a clonal event in over 50% of these diseases. [139] [140] [141] CSF3R mutations are notable because they represent a potential predictive marker for targeted therapy. Preclinical data suggest that truncating CSF3R mutations predict sensitivity to SRC inhibition and CSF3R mutations affecting the membrane proximal portion for the receptor predicts sensitivity to JAK2 inhibition. 139 The latter has been validated in clinical case reports with ruxolitinib therapy in aCML. 142 However, two separate reports have failed to identify CSF3R mutations in a stringently defıned aCML cohort and were exclusively seen in CNL. 143, 144 Nonetheless, mutational analysis for CSF3R should be performed if aCML is suspected, given the potential therapeutic implications.
Myelodysplastic Syndromes/Myeloproliferative Neoplasms-Unclassifiable
The genetic study of MDS/MPN-Unclassifıable (U) has been limited by diffıculties in the diagnostic standardization of this entity. MDS/MPN-U is defıned by having clinicopathologic features of myeloproliferation, dysplasia, and cytopenias but not meeting criteria for other well-defıned MDS/MPNs. It is hypothesized that many MDS/MPN-U cases may be reclassifıced into other WHO-defıned MDS/MPNs with mutational profıling. To this end, a recent retrospective study identifıed a clinical and genetic signature that could identify aCML among those cases initially identifıed as MDS/MPN-U. 144 More investigation is needed to better annotate disease-specifıc genetic fın-gerprints to confıdently allow for reclassifıcation of MDS/MPN cases.
Refractory Anemia with Ring Sideroblast and Thrombocytosis
Refractory anemia with ring sideroblost and thrombocytosis RARS-T) is defıned by the presence of ringed sideroblasts and a platelet count of greater than 450 x 10 8 /dL and is included as a provisional category within the group of MDS/ MPN-U by WHO. 8, 14 Similar to cases of MDS with ringed sideroblasts (RARS), the genetic landscape of RARS-T is dominated by the presence of mutations in SF3B1 that occur at a frequency reported between approximately 60 to 90%. 28, 29, 145 Other recurrent mutations identifıed in both RARS and RARS-T include TET2, ASXL1, and EZH2. 146 However, RARS-T has been demonstrated to additionally harbor mutations in JAK2 at rates approximating 50% and, less frequently, mutations in other signaling mutations such as CBL and CALR, which are rarely seen in RARS. 28, [146] [147] [148] [149] This raises the possibility that mutations in JAK2 may be responsible for the thrombocytosis uniquely seen in RARS-T.
Although conventional wisdom states that the natural history of RARS-T is relatively benign, emerging data suggest that annotation of mutations in RARS-T may reveal a more aggressive subtype. A recent report identifıed SF3B1 and JAK2 mutations as favorably prognostic and associated with improved survival compared to their mutated counterpart. For example, SF3B1 wild-type cases of RARS-T had a median survival of 3.3 years compared to 6.9 years in mutated cases.
THERAPIES IN ADULT MYELODYSPLASTIC SYNDROMES/MYELOPROLIFERATIVE NEOPLASMS
No pharmacologic agents have been demonstrated to alter the natural history of MDS/MPNs. As such, the general approach for the treatment of these groups of diseases is to focus on therapeutic strategies tailored to symptomatology with individual patients. There is little evidence to suggest that patients with asymptomatic MDS/MPN benefıt from current standard treatment. However, it is strongly recommended that all patients with MDS/MPN be considered for clinical trial when available. Allogeneic stem cell transplant has the most robust data suggesting a disease modifying effect in MDS/MPNs 94, [150] [151] [152] and should therefore be considered in higher-risk patients with MDS/MPN. Although there has been substantial progress in the prognostication of CMML cases, challenges remain in adequately risk-stratifying other MDS/MPNs for clinical transplant decision making. 48, 153, 154 Below is a summary of treatment options and their disease-specifıc supporting data.
Hypomethylating Agents
Very limited data are available for the use of HMAs for the treatment of aCML, MDS/MPN-U, or RARS-T. 155 However, robust data exist that demonstrate the activity of HMAs in CMML. Several phase II studies have demonstrated that azacitadine is active in CMML and associated with acceptable therapy-associated toxicity. 156, 157 Oral azacitadine more recently has been tested for the treatment of CMML with clinical responses seen in 35% of patients previously treated with HMA for MDS and CMML, and in 73% of patients receiving azacitadine as fırst-line therapy. 158 Decitabine also has been examined in multiple phase II trials, with response rates ranging from 10 to 58% in patients with CMML. 159 However, despite well-documented activity, no evidence exists that HMAs increase overall survival or decrease progression to AML. Therefore, we reserve this therapy for patients with CMML in which cytopenias are the predominant symptom. We would not favor HMAs in rapidly proliferative patients with CMML, given the relatively long median time to HMA response. There is no CMML-specifıc evidence to favor one HMA over another.
Lenalidomide and Interferon
There has been limited data testing the activity of lenalidomide in CMML and RARS-T. In CMML, lenalidomide has been tested in combination with metronomic doses of melphalan. Although the study was small in number, a 25 and 33% response rate was identifıed in patients with myelodysplastic and myeloproliferative CMML, respectively. 160 A case study also has reported a proliferative of CMML cases with isolated del(5q) treated with lenalidomide that achieved blast clearance and cytoreduction. In RARS-T, three case reports have demonstrated clinical activity with respect to hematologic and splenomegaly improvement irrespective of cytogenetic abnormalities. [161] [162] [163] Interferon has been tested in aCML in a limited number of cases with modest activity. 164, 165 
Cytoreductive Agents
Patients with MDS/MPN with rapid and severe myeloproliferative or constitutional symptoms should be considered for treatment with cytoreductive agents. These therapies range from induction chemotherapy to hydroxyurea and should be chosen based on performance status and other host-specifıc factors. As with HMAs, a larger clinical experience exists with cytoreductive agent in CMML compared to other MDS/ MPNs. Several studies have reported the effıcacy of the topoisomerase inhibitors topotecan and etoposide both as single agent and in combination with cytarabine. [166] [167] [168] Other trials have examined combination with arsenic or all-trans retinoic acid (ATRA) with modest results. 169, 170 These two trials are notable because they represent two of the only MDS/MPNspecifıc studies to date. The only randomized study that has been performed in CMML randomly assigned 105 patients with CMML to receive hydroxyurea or etoposide. Surprisingly, this trial demonstrated a median overall survival of 20 months in the hydroxyurea group compared to 9 months in the etoposide arm, suggesting inferior diseasemodifying capacity for etoposide in CMML. 168 Induction chemotherapy has been used in CMML based on extrapolation from MDS. In our practice, we recommend induction chemotherapy in patients with extreme or symptomatic leukocytosis, massive splenomegaly, or severe constitutional symptoms that are refractory to hydroxyurea or other less-intensive approaches. Although it is not well addressed in the literature, a minority of patients achieves a complete response and are capable of being considered for allogeneic stem cell transplant. However, limited evidence is available that carefully weighs these response rates against the substantial toxicities associated with induction-type chemotherapy.
Future Therapies
Although other therapeutic options have the potential to improve the symptomatology of patients with MDS/MPN, the current pharmacologic landscape is limited. Ongoing studies testing JAK2 inhibitors in aCML and CMML hold promise 171 (NCT02092324 and NCT01776723). However, only a small number of studies currently are addressing MDS/MPN cases specifıcally. Hopefully, improved molecular understanding of MDS/MPNs will lead to disease-specifıc clinical trials with promising agents that will affect the natural history of this group of lethal diseases.
CONCLUSION
Our burgeoning knowledge of the molecular complexity of MDS and MDS/MPNs is rapidly providing novel insights into the pathobiology of these diseases. The clinical application and relevance of these insights currently is largely limited to the refınement of prognostic risk models. Hopefully, this knowledge ultimately will translate into targeted therapies with the potential to change the natural history of these diseases. Presently, judicial selection of patients for treatment with currently available therapies, including alloSCT and nontransplant disease-modifying therapies, coupled with an improved knowledge into the best approaches to use these therapies, is of paramount importance. Given the current paucity of effective therapies for these diseases, an urgent need remains for the development of novel approaches and combinations with the potential of moving the fıeld forward.
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